SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Eightco Holdings, Inc. is a publicly traded holding company, which operates in the consumer products and e-commerce markets, focusing on developing and deploying innovative technology, and capital solutions to empower small to medium-sized businesses. It operates through the North America and Europe geographical segments. The company was founded in 1966 and is headquartered in Easton, PA.

Eightco Holdings Inc

Eightco Holdings ($OCTO) is trending due to a significant private placement announcement and a strategic investment related to launching a Worldcoin treasury strategy, sparking a massive pre-market surge and short squeeze. The community is actively discussing the potential for further gains, with some drawing comparisons to other high-flying stocks and speculating on how high it can go, while others caution about potential dilution risks. News of Dan Ives joining as Chairman seems to be adding fuel to the fire.

AST Spacemobile, Inc. engages in building a broadband cellular network in space to operate directly with standard, unmodified mobile devices based on an extensive IP and patent portfolio. It focuses on providing mobile broadband services with global coverage to all end-users, without the need to purchase special equipment. The company was founded by Abel Avellan on May 31, 2017 and is headquartered in Midland, TX.

AST SpaceMobile Inc - Ordinary Shares - Class A

AST SpaceMobile Inc

ASTS is trending downwards as investors react to news of a competitor, SpaceX, acquiring spectrum, leading to concerns about increased competition. The community is debating the impact of this acquisition, with some bulls arguing that it validates the technology and creates a duopoly, while bears worry about ASTS's ability to compete with a larger player. Discussions also revolve around potential dilution and the importance of upcoming satellite launches for regaining market confidence.

QuantumScape Corp. engages in developing next-generation solid-state lithium-metal batteries. The company’s next-generation batteries are designed to enable greater energy density, faster charging, and enhanced safety to support the transition away from legacy energy sources toward a lower-carbon future. The company was founded by Jagdeep Singh, Tim Holme, and Fritz B. Prinz in May 2010 and is headquartered in San Jose, CA.

QuantumScape Corp - Ordinary Shares - Class A

QuantumScape Corp

QuantumScape is trending after a live demo of its solid-state batteries powering a Ducati motorcycle at the IAA Mobility event, sparking enthusiasm among investors. The community is buzzing about the potential for the technology in EVs and motorcycles, along with possible partnerships with major automotive manufacturers. Despite a long timeline to commercialization, some believe the demonstration validates the long-term potential of solid-state battery technology.

Dogecoin is a cryptocurrency based on the popular "Doge" Internet meme and features a Shiba Inu on its logo. Dogecoin is a Litecoin fork. Introduced as a "joke currency" on 6 December 2013, Dogecoin quickly developed its own online community and reached a capitalization of US$60 million in January 2014. Compared with other cryptocurrencies, Dogecoin had a fast initial coin production schedule: 100 billion coins were in circulation by mid-2015, with an additional 5.256 billion coins every year thereafter. As of 30 June 2015, the 100 billionth Dogecoin had been mined.   Dogecoin was created by Billy Markus from Portland, Oregon and  Jackson Palmer from Sydney, Australia. Both wanted to create a fun cryptocurrency that will appeal beyond the core Bitcoin audience. Dogecoin is primarily used as a tipping system on Reddit and Twitter where users tip each other for creating or sharing good content. The community is very active in organising fundraising activities for deserving causes.  The developers of Dogecoin haven’t made any major changes to the coin since 2015. This means that Dogecoin could get left behind and is why Shibas are leaving Dogecoin to join more advanced platforms like Ethereum. One of Dogecoin strengths is its relaxed and fun-loving community. However, this is also a weakness because other currencies are way more professional.  To purchase Dogecoin, it involves downloading a crypto wallet, setting up a crypto exchange account and then trading away for your desired crypto currency. Once we have set up an account with a DOGE currency exchange and deposited some funds, you are ready to start trading.

Dogecoin

Dogecoin is trending amid speculation surrounding a potential Dogecoin ETF, with the community buzzing about possible approval and its impact. Some traders point to technical indicators suggesting bullish momentum, while others are discussing the potential for Dogecoin to reach new all-time highs. The conversation also includes debate around Dogecoin's utility and its future in the broader crypto market.

Robinhood Markets, Inc is a financial services platform, which engages in the provision of retail brokerage and offers trading in U.S. listed stocks and Exchange Traded Funds, related options, and cryptocurrency trading, as well as cash management, which includes debit cards services. The company was founded by Vladimir Tenev and Baiju Prafulkumar Bhatt in 2013 and is headquartered in Menlo Park, CA.

Robinhood Markets Inc - Ordinary Shares - Class A

Robinhood Markets Inc

Robinhood is trending due to its upcoming inclusion in the S&P 500, replacing Caesars Entertainment, which has sparked bullish sentiment and discussions around potential impacts on the stock's price. The community is analyzing technical levels, anticipating increased buying pressure from index funds, and debating whether this event has already been priced in. Some traders are also looking forward to the company's upcoming event, anticipating further catalysts.

Opendoor Technologies, Inc. engages in the operation of buying, selling, and trading of residential properties online. The company was founded by Eric Wu on December 30, 2013, and is headquartered in Tempe, AZ.

Opendoor Technologies Inc

OPEN is trending due to a potential short squeeze, with community members discussing strategies to trap shorts and drive the price higher. Anticipation of upcoming catalysts like interest rate cuts and a new CEO announcement are fueling bullish sentiment. Despite some skepticism and concerns about a possible pullback, the overall mood is optimistic, with many eyeing double-digit targets.

Seres Therapeutics, Inc. engages in the development of biological drugs through microbiome therapeutics platform. Its product pipeline includes SER-109, SER-287, SER-301, and SER-401. The company was founded by Geoffrey von Maltzahn, David A. Berry, and Noubar B. Afeyan on October 18, 2010 and is headquartered in Cambridge, MA.

Seres Therapeutics Inc

MCRB is trending amid speculation of a potential acquisition or merger, fueled by recent executive changes and ongoing discussions with multiple parties. Community members are focused on the possibility of a short squeeze, given the stock's low float and high short interest. Buyers are speculating about a partnership or merger and what that could mean for long term growth for the company.

CorMedix, Inc. is a pharmaceutical and medical device company, which engages in the development and commercialization of therapeutic products for the prevention and treatment of diseases and conditions. The company was founded by Antony E. Pfaffle on July 28, 2006 and is headquartered in Berkeley Heights, NJ.

CorMedix Inc

CorMedix is trending due to its strategic investment in Talphera (TLPH) for Niyad, a potential CRRT treatment, sparking discussions about a possible acquisition and future roll-up company strategy. Community members are weighing the risks and potential rewards, including possible buy-out scenarios, while some express reservations about the company's expanding ventures and the impact of the Melinta deal. Bullish sentiment remains, with some eyeing a potential institutional influx and a climb towards higher valuations amid discussions on financial guidance and sales estimates.

AppLovin Corp. engages in the development and operation of a mobile marketing platform. It offers AppDiscovery, MAX, Adjust, and SparkLabs. Its software-based platform caters to mobile application developers to improve the marketing and monetization of applications. The company was founded by Andrew Karam, John Krystynak, and Adam Foroughi in 2011 and is headquartered in Palo Alto, CA.

Applovin Corp - Ordinary Shares - Class A

Applovin Corp

AppLovin is trending as investors discuss its potential S&P 500 inclusion, with community members analyzing technical levels and anticipating a breakout. Bullish sentiment is fueled by the company's strong performance and perceived undervaluation compared to peers. Some traders express caution, citing potential overvaluation and historical patterns after index additions.

Rapport Therapeutics, Inc. engages in the discovery and development of transformational small molecule medicines for patients suffering from central nervous system disorders. It develops the RAP (receptor associated proteins) technology platform. The company was founded by Steven M. Paul and David Bredt in February 2022 and is headquartered in Boston, MA.

Rapport Therapeutics Inc.

Rapport Therapeutics Inc

Rapport Therapeutics is trending after announcing positive topline results from its Phase 2a clinical trial, leading to a significant pre-market surge and sparking excitement among investors. The community is focused on the potential for future gains and speculating on short squeeze opportunities, while also discussing the company's fundamentals and comparisons to other biotech stocks. The stock's movement is attributed to its low float and the buzz around the trial's outcome within the neuroscience sector.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Keros Therapeutics, Inc. (KROS) Reports Q2 Loss, Beats Revenue Estimates

Keros Therapeutics (KROS) delivered earnings and revenue surprises of +33.33% and +135.95%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

KROS vs. EXAS: Which Stock Should Value Investors Buy Now?

KROS vs. EXAS: Which Stock Is the Better Value Option?

Will Reblozyl Enable BMY to Offset the Impact of Generic Competition? 

Reblozyl sales surged 35% in Q1 for BMY, but a failed phase III study clouds expansion plans amid stiff anemia drug competition.

RCKT Stock Up on FDA's RMAT Tag to Gene Therapy for Heart Failure

Rocket Pharmaceuticals jumps 16.8% as FDA grants RMAT status to RP-A601 on positive phase I heart disease data.

FDA Advisory Panel Votes Against Approval of GSK's Blenrep Combo

GSK stock falls as an FDA panel votes against its Blenrep combo, casting doubt on U.S. approval hopes.

KRYS Begins Dosing With Gene Therapy in Rare Eye Disease, Stock Up

Krystal Biotech climbs after dosing begins in a phase I/II trial for KB801, a gene therapy eye drop targeting neurotrophic keratitis.

RYTM Stock Rises on Upbeat Acquired Hypothalamic Obesity Study Data

Rhythm Pharmaceuticals jumps 36.6% after its oral drug bivamelagon shows strong BMI and hunger reductions in a phase II study in acquired hypothalamic obesity.

Shares of Keros Therapeutics, Inc. (KROS) traded 14% higher on Thursday morning after the company <a target="_blank" rel="noopener noreferrer nofollow" href="https://ir.kerostx.com/news-releases/news-release-details/keros-therapeutics-announces-review-strategic-alternatives">adopted</a> a poison pill plan to fend off hostile takeovers by a number of investors that have rapidly accumulated a significant number of shares in the firm.The defense strategy, a limited-duration stockholder rights plan, will reduce the likelihood that a hostile group gains control of Keros through open-market accumulation without paying all stockholders an appropriate control premium.As per the plan, if any entity acquires ownership of 10% or more, or 15% in the case of passive institutional investors, of Keros’ outstanding common stock in a transaction not approved by the Board, other shareholders can purchase additional shares at a discount.The company adopted the plan after a number of investors who accumulated the company’s common stock indicated a desire to gain control over the firm. This included an individual investor who informed the company that it holds 11.2% of Keros’ outstanding common stock as of April 6, 2025. The company did not name the investor.Keros said that its board has also decided to initiate a formal review process to evaluate strategic alternatives to maximize stockholder value for the company.A committee will consider a range of strategic alternatives including the sale of the company or other business combination transaction, continued investment in its pipeline, or return of excess capital to stockholders.The company added that there is no assurance the review will lead to the company pursuing a transaction.On Stocktwits, retail sentiment around Keros jumped from ‘neutral’ to ‘extremely bullish’ while message volume rose from ‘low’ to ‘extremely high’ over the past 24 hours.<figure class="image"><img style="aspect-ratio:647/151;" src="https://news.stocktwits-cdn.com/Screenshot_2025_04_10_at_11_27_14_AM_png_386737346f.webp" alt="KROS's Sentiment Meter and Message Volume as of 11:30 a.m. ET on April 10, 2025 | Source: Stocktwits" width="647" height="151"><figcaption>KROS's Sentiment Meter and Message Volume as of 11:30 a.m. ET on April 10, 2025 | Source: Stocktwits</figcaption></figure> <a href="https://stocktwits.com/symbol/KROS">KROS shares</a> are down by about 26% year-to-date and 81% over the past 12 months.Also See: <a href="https://stocktwits.com/news-articles/markets/equity/polestar-q1-sales-jump-76-percent-on-newer-models/chfYiCFRbBr">Polestar Q1 Sales Jump 76% On Newer Models: Retail Sentiment Brightens</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

Keros Therapeutics Adopts Defense Strategy Against Potential Hostile Takeover, Explores Sale: Retail’s Overjoyed

The company said the plan aims to reduce the likelihood of any entity or person gaining control of Keros through open-market accumulation without paying all stockholders an appropriate control premium.

Equity

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Keros Therapeutics, Inc. - KROS

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Keros Therapeutics, Inc. - KROS INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Keros...

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Keros Therapeutics, Inc. - KROS

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Keros Therapeutics, Inc. - KROS SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of...

Keros Therapeutics, Inc. operates as a clinical stage biopharmaceutical company. It focuses on the discovery, development and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with unmet medical need. The company was founded in 2015 and is headquartered in Lexington, MA.

KROS
Keros Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest KROS News

KROS Keros Therapeutics Inc